Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design

Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Gavin Dabrera, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2023.09.28.23296290
Back to top
Posted September 29, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design
Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Gavin Dabrera, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2023.09.28.23296290; doi: https://doi.org/10.1101/2023.09.28.23296290
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area